Jeff Martin

Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative Platform LEAWOOD, Kan., Feb. 11, 2026 — Etienna Bio, Inc., a regenerative biotechnology company developing an autologous adipose-derived cell platform for aesthetic and reconstructive applications, today…

Etienna Bio Secures Exclusive Worldwide License from UMass Chan Medical School for Novel Adipose-Derived Regenerative Platform LEAWOOD, Kan., Jan. 09, 2026 (GLOBE NEWSWIRE) — Etienna Bio, Inc., a biotechnology company focused on next-generation autologous and cell-enabled biomaterials for regenerative and…